Myogenic tissue nanotransfection improves muscle torque recovery following volumetric muscle loss.

Myogenic tissue nanotransfection improves muscle torque recovery following volumetric muscle loss.

NPJ Regenerative medicine (2022-10-21)

Andrew Clark, Subhadip Ghatak, Poornachander Reddy Guda, Mohamed S El Masry, Yi Xuan, Amy Y Sato, Teresita Bellido, Chandan K Sen

PMID36266362

ZUSAMMENFASSUNG

This work rests on our non-viral tissue nanotransfection (TNT) platform to deliver MyoD (TNTMyoD) to injured tissue in vivo. TNTMyoD was performed on skin and successfully induced expression of myogenic factors. TNTMyoD was then used as a therapy 7 days following volumetric muscle loss (VML) of rat tibialis anterior and rescued muscle function. TNTMyoD is promising as VML intervention.

MATERIALIEN

Produktnummer

Marke

Produktbeschreibung

F8630

Sigma-Aldrich

Fibrinogen aus Rinderplasma, Type I-S, 65-85% protein (≥75% of protein is clottable)

T7326

Sigma-Aldrich

Thrombin aus Rinderplasma, ≥60 NIH units/mg protein (biuret)